{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:25:48Z","timestamp":1758043548271,"version":"3.44.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Chronic low-grade inflammation constitutes a shared pathological mechanism linking type 2 diabetes mellitus (T2DM) and malignancies. While preclinical evidence suggests SGLT2 inhibitors (SGLT2i) may attenuate chronic inflammation, clinical data regarding their protective effects against multi-system inflammatory complications during anti-tumor therapy remain scarce.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This study examined the association between SGLT2i use and the risk of cardiopulmonary inflammatory complications following anti-tumor therapy in cancer patients with diabetes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective, propensity score-matched cohort study at the First Affiliated Hospital of Xi'an Jiaotong University. Patients diagnosed with T2DM and cancer between March 2017 and March 2024, who survived over one year after initiating anti-tumor therapy, were included. Participants were stratified into SGLT2i users and non-users based on pre-treatment exposure. Non-SGLT2i users were matched 1:1 to users by age, sex, cancer stage, hemoglobin A1c (HbA1c), and estimated glomerular filtration rate (eGFR) levels. The primary outcome was a composite of cardiopulmonary inflammatory complications (pneumonia, pleural effusion, and pericardial effusion).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 1,183 eligible patients with T2DM and cancer, 103 received SGLT2i before anti-tumor therapy (SGLT2i group) and were matched with 103 non-SGLT2i users. Over the median follow-up period of 48 months, the SGLT2i group had a significantly lower risk of composite events (15.53% vs. 35.92%, <jats:italic>p<\/jats:italic>\u2009=\u20090.002) than the non-SGLT2i group, with reduced risks for pneumonia (9.71% vs. 22.33%, <jats:italic>p<\/jats:italic>\u2009=\u20090.030), pleural effusion (5.83% vs. 17.48%, <jats:italic>p<\/jats:italic>\u2009=\u20090.025), and pericardial effusion (2.91% vs. 10.68%, <jats:italic>p<\/jats:italic>\u2009=\u20090.030).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In cancer patients with diabetes, pre-treatment SGLT2i use is associated with reduced risks of cardiorespiratory inflammatory complications. Robust prospective studies are warranted to confirm the role of SGLT2i in mitigating multi-system inflammatory risks in this cohort.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2025.1657240","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T05:35:29Z","timestamp":1757655329000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["SGLT2i use is associated with reduced risks of cardiopulmonary inflammatory complications in cancer patients with diabetes: a retrospective cohort study"],"prefix":"10.3389","volume":"12","author":[{"given":"Dan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanlin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyu","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(24)02317-1","article-title":"Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants","volume":"404","year":"2024","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.2337\/dc24-S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S2213-8587(17)30366-2","article-title":"Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment","volume":"6","author":"Pearson-Stuttard","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1038\/s41591-024-03123-2","article-title":"The burden of diabetes-associated multiple long-term conditions on years of life spent and lost","volume":"30","author":"Gregg","year":"2024","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","article-title":"Inflammation in obesity, diabetes, and related disorders","volume":"55","author":"Rohm","year":"2022","journal-title":"Immunity"},{"key":"B7","doi-asserted-by":"publisher","first-page":"122390","DOI":"10.1016\/j.lfs.2023.122390","article-title":"Chronic inflammation and cancer; the two sides of a coin","volume":"338","author":"Fernandes","year":"2024","journal-title":"Life Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an international cardio-oncology society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1007\/s40618-024-02417-z","article-title":"Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian association of medical oncology (AIOM), Italian association of medical diabetologists (AMD), Italian society of diabetology (SID), Italian society of endocrinology (SIE), Italian society of pharmacology (SIF) multidisciplinary critical view","volume":"47","author":"Natalicchio","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"B10","doi-asserted-by":"publisher","first-page":"102062","DOI":"10.1016\/j.esmoop.2023.102062","article-title":"Diabetes management in cancer patients. An Italian association of medical oncology, Italian association of medical diabetologists, Italian society of diabetology, Italian society of endocrinology and Italian society of pharmacology multidisciplinary consensus position paper","volume":"8","author":"Silvestris","year":"2023","journal-title":"ESMO Open"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e3922","DOI":"10.1002\/cbf.3922","article-title":"SGLT2 Inhibitors and AMPK: the road to cellular housekeeping?","volume":"42","author":"Safaie","year":"2024","journal-title":"Cell Biochem Funct"},{"key":"B12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/antiox13010016","article-title":"Anti-inflammation and anti-oxidation: the key to unlocking the cardiovascular potential of SGLT2 inhibitors and GLP1 receptor agonists","volume":"13","author":"Myasoedova","year":"2023","journal-title":"Antioxidants"},{"key":"B13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/immuno5010011","article-title":"Anti-inflammatory and anti-oxidative effects of GLP1-RAs and SGLT2i: the guiding star towards cardiovascular protection in type 2 diabetes","volume":"5","author":"Marcon","year":"2025","journal-title":"Immuno"},{"key":"B14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.tem.2024.02.003","article-title":"Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors","volume":"35","author":"Mashayekhi","year":"2024","journal-title":"Trends Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1210\/clinem\/dgac558","article-title":"Sodium-glucose cotransporter 2 inhibitors and the risk of pneumonia and septic shock","volume":"107","author":"Li","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/thorax-2024-221906","article-title":"Comparative estimate of glucose-lowering therapies on risk of incident pneumonia and severe sepsis: an analysis of real-world cohort data","volume":"80","author":"Henney","year":"2024","journal-title":"Thorax"},{"key":"B17","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jchf.2022.03.006","article-title":"Sodium-glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines","volume":"10","author":"Gongora","year":"2022","journal-title":"JACC Heart Fail"},{"key":"B18","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jaccao.2023.03.011","article-title":"The association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer","volume":"5","author":"Abdel-Qadir","year":"2023","journal-title":"JACC Cardio Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jchf.2023.08.026","article-title":"SGLT2 inhibitor use and risk of clinical events in patients with cancer therapy-related cardiac dysfunction","volume":"12","author":"Avula","year":"2024","journal-title":"JACC Heart Fail"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1364110","DOI":"10.3389\/fphar.2024.1364110","article-title":"Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database","volume":"15","author":"Alenzi","year":"2024","journal-title":"Front Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/14740338.2023.2284992","article-title":"Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Muhammed","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"B22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/M18-3136","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study","volume":"171","author":"Dave","year":"2019","journal-title":"Ann Intern Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"B25","doi-asserted-by":"publisher","first-page":"21756","DOI":"10.1038\/s41598-023-48678-1","article-title":"Sodium-glucose cotransporter-2 inhibitors improve clinical outcomes in patients with type 2 diabetes mellitus undergoing anthracycline-containing chemotherapy: an emulated target trial using nationwide cohort data in South Korea","volume":"13","author":"Hwang","year":"2023","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1007\/s00125-024-06102-x","article-title":"Diabetes and infection: review of the epidemiology, mechanisms and principles of treatment","volume":"67","author":"Holt","year":"2024","journal-title":"Diabetologia"},{"key":"B27","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/pds.5192","article-title":"SGLT-2 inhibitors and the risk of hospitalization for community-acquired pneumonia: a population-based cohort study","volume":"30","author":"Brunetti","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1719","DOI":"10.1210\/clinem\/dgab818","article-title":"Association between SGLT2 inhibitors vs DPP-4 inhibitors and risk of pneumonia among patients with type 2 diabetes","volume":"107","author":"Au","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12916-023-02765-2","article-title":"Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study","volume":"21","author":"Jeong","year":"2023","journal-title":"BMC Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.trecan.2022.07.002","article-title":"Inflammation: the incubator of the tumor microenvironment","volume":"8","author":"Denk","year":"2022","journal-title":"Trends Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/prd.12603","article-title":"Resolution of chronic inflammation and cancer","volume":"96","author":"Tezcan","year":"","journal-title":"Periodontol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/bph.13741","article-title":"Dapagliflozin-lowered blood glucose reduces respiratory Pseudomonas aeruginosa infection in diabetic mice","volume":"174","author":"Astrand","year":"2017","journal-title":"Br J Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin","volume":"20","author":"Quagliariello","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"10146","DOI":"10.3390\/ijms231710146","article-title":"Dapagliflozin mitigates doxorubicin-caused myocardium damage by regulating AKT-mediated oxidative stress, cardiac remodeling, and inflammation","volume":"23","author":"Hsieh","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/oby.23331","article-title":"SGLT Inhibitors on weight and body mass: a meta-analysis of 116 randomized-controlled trials","volume":"30","author":"Cheong","year":"2022","journal-title":"Obesity"},{"key":"B37","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.cmet.2023.12.018","article-title":"Prevention of cardiorenal complications in people with type 2 diabetes and obesity","volume":"36","author":"Drucker","year":"2024","journal-title":"Cell Metab"},{"key":"B38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41574-024-01047-y","article-title":"Inflammation and resolution in obesity","volume":"21","author":"Sot\u00e1k","year":"2025","journal-title":"Nat Rev Endocrinol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1045235","DOI":"10.3389\/fphar.2022.1045235","article-title":"The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"110621","DOI":"10.1016\/j.diabres.2023.110621","article-title":"Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: a systematic review and meta-analysis of randomized controlled trials","volume":"198","author":"Spiazzi","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"B41","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/17512433.2024.2439970","article-title":"Revisiting the association between sodium-glucose cotransporter-2 inhibitors and the risk of neoplasm in patients with type 2 diabetes: new insights from an updated systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Wang","year":"2025","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jaccao.2024.01.007","article-title":"The cardioprotective and anticancer effects of SGLT2 inhibitors: JACC: cardioOncology state-of-the-art review","volume":"6","author":"Dabour","year":"2024","journal-title":"JACC CardioOncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"101688","DOI":"10.1016\/j.xcrm.2024.101688","article-title":"The effect of SGLT2 inhibition on prostate cancer: mendelian randomization and observational analysis using electronic healthcare and cohort data","volume":"5","author":"Zheng","year":"2024","journal-title":"Cell Rep Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/s41416-023-02177-2","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival","volume":"128","author":"Luo","year":"2023","journal-title":"Br J Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/cac2.70028","article-title":"Risk of colorectal cancer and cancer-related mortality in type 2 diabetes patients treated with metformin, SGLT-2 inhibitors, or their combination","volume":"45","author":"Mao","year":"2025","journal-title":"Cancer Commun"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1111\/dom.15249","article-title":"Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (\u226565 years) with type 2 diabetes: a randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY)","volume":"25","author":"Yabe","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1238399","DOI":"10.3389\/fendo.2023.1238399","article-title":"Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials","volume":"14","author":"Li","year":"2023","journal-title":"Front Endocrinol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1256548","DOI":"10.3389\/fendo.2023.1256548","article-title":"Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials","volume":"14","author":"Chen","year":"2023","journal-title":"Front Endocrinol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"101367","DOI":"10.1016\/j.diabet.2022.101367","article-title":"Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors","volume":"48","author":"Wu","year":"2022","journal-title":"Diabetes Metab"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s00210-023-02685-1","article-title":"Sodium-glucose cotransporter-2 inhibitor in risk of sepsis\/septic shock among patients with type 2 diabetes mellitus-a retrospective analysis of nationwide medical claims data","volume":"397","author":"Hu","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1657240\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T05:35:30Z","timestamp":1757655330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1657240\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":50,"alternative-id":["10.3389\/fcvm.2025.1657240"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1657240","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"article-number":"1657240"}}